IMCR · Immunocore Holdings plc American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IMCR by emailGet an email when IMCR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMCR, unsubscribe in one click. Privacy
📣 What IMCR Says Is Next
second half of 2026 · “The Company plans to file a CTA or investigational new drug (IND) application for IMC-U120AI (CD1a x PD1) in the second half of 2026.”
Company press release, May 6, 2026 · SEC filing
second half of 2026 · “Additional Phase 1 MAD data is expected to be presented in the second half of 2026.”
Company press release, May 6, 2026 · SEC filing
in 2027 · “The Company expects to present initial data in 2027.”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IMCR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMCR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.